Abbott Laboratories (ABT) - Total Liabilities
Based on the latest financial reports, Abbott Laboratories (ABT) has total liabilities worth $32.92 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Abbott Laboratories - Total Liabilities Trend (1985–2024)
This chart illustrates how Abbott Laboratories's total liabilities have evolved over time, based on quarterly financial data. See ABT net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Abbott Laboratories Competitors by Total Liabilities
The table below lists competitors of Abbott Laboratories ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BlackRock Inc
NYSE:BLK
|
USA | $106.92 Billion |
|
Charles Schwab Corp
NYSE:SCHW
|
USA | $765.00 Million |
|
Deere & Company
NYSE:DE
|
USA | $77.08 Billion |
|
Deutsche Telekom AG
XETRA:DTE
|
Germany | €195.56 Billion |
|
Gilead Sciences Inc
NASDAQ:GILD
|
USA | $36.41 Billion |
|
Southern Copper Corporation
NYSE:SCCO
|
USA | $10.07 Billion |
|
AT&T Inc.
NYSE:T
|
USA | $293.57 Billion |
|
Union Pacific Corporation
NYSE:UNP
|
USA | $50.23 Billion |
Liability Composition Analysis (1985–2024)
This chart breaks down Abbott Laboratories's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Abbott Laboratories stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.52 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abbott Laboratories's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abbott Laboratories (1985–2024)
The table below shows the annual total liabilities of Abbott Laboratories from 1985 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $33.51 Billion | -2.54% |
| 2023-12-31 | $34.39 Billion | -8.38% |
| 2022-12-31 | $37.53 Billion | -4.18% |
| 2021-12-31 | $39.17 Billion | -0.94% |
| 2020-12-31 | $39.55 Billion | +8.09% |
| 2019-12-31 | $36.59 Billion | +0.37% |
| 2018-12-31 | $36.45 Billion | -19.27% |
| 2017-12-31 | $45.15 Billion | +41.33% |
| 2016-12-31 | $31.95 Billion | +60.38% |
| 2015-12-31 | $19.92 Billion | +1.45% |
| 2014-12-31 | $19.64 Billion | +11.03% |
| 2013-12-31 | $17.69 Billion | -56.25% |
| 2012-12-31 | $40.42 Billion | +13.07% |
| 2011-12-31 | $35.75 Billion | -3.34% |
| 2010-12-31 | $36.99 Billion | +25.30% |
| 2009-12-31 | $29.52 Billion | +18.36% |
| 2008-12-31 | $24.94 Billion | +13.70% |
| 2007-12-31 | $21.94 Billion | -0.85% |
| 2006-12-31 | $22.12 Billion | +50.24% |
| 2005-12-31 | $14.73 Billion | +1.97% |
| 2004-12-31 | $14.44 Billion | +5.85% |
| 2003-12-31 | $13.64 Billion | +0.36% |
| 2002-12-31 | $13.59 Billion | -4.51% |
| 2001-12-31 | $14.24 Billion | +112.10% |
| 2000-12-31 | $6.71 Billion | -4.70% |
| 1999-12-31 | $7.04 Billion | -6.12% |
| 1998-12-31 | $7.50 Billion | +6.23% |
| 1997-12-31 | $7.06 Billion | +12.01% |
| 1996-12-31 | $6.31 Billion | +25.71% |
| 1995-12-31 | $5.02 Billion | +12.10% |
| 1994-12-31 | $4.47 Billion | +11.48% |
| 1993-12-31 | $4.01 Billion | +11.69% |
| 1992-12-31 | $3.59 Billion | +17.73% |
| 1991-12-31 | $3.05 Billion | +11.82% |
| 1990-12-31 | $2.73 Billion | +28.44% |
| 1989-12-31 | $2.13 Billion | -9.97% |
| 1988-12-31 | $2.36 Billion | +2.98% |
| 1987-12-31 | $2.29 Billion | +9.85% |
| 1986-12-31 | $2.09 Billion | +30.61% |
| 1985-12-31 | $1.60 Billion | -- |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more